Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
LYEL | US
-0.01
-0.81%
Healthcare
Biotechnology
30/06/2024
04/10/2024
1.22
1.25
1.25
1.21
Lyell Immunopharma Inc. a clinical-stage cell therapy company engages in developing T-cell reprogramming technologies for patients with solid tumors. It develops therapies using an ex vivo genetic reprogramming technologies such as c-Jun overexpression and NR4A3 gene knockout to endow resistance to T-cell exhaustion; and an ex vivo epigenetic reprogramming technologies including Epi-R to generate population of T cells with durable stemness and Stim-R a proprietary synthetic cell mimetic. The company's pipeline includes LYL797 a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T-cell product candidate for the treatment of various solid tumors; LYL845 an epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate that targets multiple solid tumors; LYL119 a CAR T-cell product candidate for enhanced cytotoxicity. The company was incorporated in 2018 and is headquartered in South San Francisco California.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Negative Momentum (Declining Price)
Price Below SMA10D
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
Low negative Beta, possible Low Liquidity (< -0.4)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
99.0%1 month
108.8%3 months
99.6%6 months
109.1%-
-
0.68
0.11
0.09
0.25
1.94K
-
-204.47M
312.32M
312.32M
-
-396.37K
-
-51.90
-32.26
24.74
7.33
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.41
Range1M
0.51
Range3M
0.83
Rel. volume
0.34
Price X volume
316.13K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Nautilus Biotechnology Inc. | NAUT | Biotechnology | 2.71 | 339.86M | -0.73% | n/a | 13.86% |
GH Research PLC Ordinary Shares | GHRS | Biotechnology | 6.49 | 337.66M | 2.69% | n/a | 0.38% |
AC Immune SA | ACIU | Biotechnology | 3.38 | 334.42M | -2.87% | n/a | 0.00% |
XOMA Corporation | XOMA | Biotechnology | 27.64 | 323.51M | 0.95% | n/a | 121.93% |
MeiraGTx Holdings plc | MGTX | Biotechnology | 4.15 | 320.31M | -1.89% | n/a | 109.40% |
ADC Therapeutics SA | ADCT | Biotechnology | 3.29 | 318.10M | 8.22% | n/a | -94.48% |
Aldeyra Therapeutics Inc | ALDX | Biotechnology | 5.34 | 317.31M | 0.75% | n/a | 15.90% |
Cerus Corporation | CERS | Biotechnology | 1.7 | 315.00M | 0.59% | n/a | 199.34% |
Immutep Limited | IMMP | Biotechnology | 2.05 | 314.34M | -3.07% | n/a | 0.84% |
Monte Rosa Therapeutics Inc | GLUE | Biotechnology | 5.09 | 312.39M | -5.57% | n/a | 19.74% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 21.28 | 334.47M | -4.23% | n/a | 286.96% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.47 | 328.78M | 0.21% | 13.24 | 0.00% |
MCBC Holdings Inc | MCFT | Recreational Vehicles | 17.64 | 292.95M | -0.56% | 35.53 | 26.82% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 23.62 | 261.38M | 4.61% | 17.90 | -621.78% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 13.5 | 219.91M | 1.89% | 8.52 | 39.79% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 31.64 | 90.86M | -0.32% | 5.47 | 19.82% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14 | 87.66M | -1.27% | 14.62 | 7.10% |
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 7.64 | 83.40M | -1.93% | n/a | 58.43% |
Urban One Inc | UONEK | Broadcasting - Radio | 1.02 | 57.65M | -4.67% | n/a | 268.43% |
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 12.89 | 19.79M | -2.50% | n/a | 204.46% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 0.25 | 0.76 | Cheaper |
Ent. to Revenue | 1,938.09 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 0.68 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 99.63 | 74.67 | Riskier |
Debt to Equity | 0.11 | -1.82 | Expensive |
Debt to Assets | 0.09 | 0.26 | Cheaper |
Market Cap | 312.32M | 3.73B | Emerging |